Tarceva and AT-101 for Patients With Advanced Non-Small Cell Lung Cancer
Status:
Withdrawn
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study the safety and effectiveness of oral AT-101 when given with the
standard dose of erlotinib (Tarceva)to patients who are older that 18 and who have advanced
non-small cell lung cancer, who have relapsed or progressed on prior platinum-based
chemotherapy.
It is proposed that the effects of AT-101 may improve the clinical benefit of erlotinib in
patients with advanced NSCLC.